24 March, 2026 16:58:35 IST 
Swiss speciality chemicals firm, Clariant, is expanding its Clear Lake, Texas, site to include excipient GMP-compliant manufacturing of pharmaceutical-grade polyethylene glycol (PEG) excipients, significantly improving their availability and reliability for North American customers, with extended reach to Latin America.
The Clear Lake facility represents Clariant’s first US manufacturing site dedicated to producing pharmaceutical-grade PEG excipients.
The facility will allow Clariant to deliver tangible operational benefits that directly support pharmaceutical customers’ production planning and business continuity. Regional manufacturing translates to significantly shorter lead times, allowing customers to respond more quickly to market demands and reduce inventory carrying costs while offering a more competitive price value. Enhanced supply continuity provides the predictability that pharmaceutical manufacturers require for complex production schedules and regulatory compliance.
Excipient GMP compliance ensures that all manufacturing processes align with international pharmaceutical excipient standards, providing customers with the documentation, traceability, and quality assurance required for regulated pharmaceutical production. Clariant’s pharmaceutical-grade PEGs are registered in relevant pharmacopoeias and feature negligible toxicity profiles, making them suitable for a wide range of applications.
